To include your compound in the COVID-19 Resource Center, submit it here.

Flagship’s Cellarity maps out network-based drug discovery

Flagship launches Cellarity to deploy single cell technologies to find compounds that hit whole networks

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target.

With $50 million in funding from Flagship Pioneering, the company uses single cell technologies and machine learning to generate maps of disease-relevant molecular networks. The company’s more than 250 disease-focused “Cellarity Maps” then serve as

Read the full 650 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE